Ocuphire Pharma Inc.
OCUP
|
$1.69
1.2%
27K
|
Health Technology
(0.0% 1d) (-15.7% 1m) (-72.9% 1y) (0.0% 2d) (-4.0% 3d) (-5.1% 7d) (159.31% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 41,934,595
http://www.ocuphire.com
Sec Filling | Patents | 5 employees
(US) Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
eye treatment
add to watch list Paper trade email alert is off
Press-releases
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Published: 2024-04-11 (Crawled : 14:00) - globenewswire.com
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: -1.08%
H: 1.63%
C: -2.72%
first solution light treatment for study
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
VTRS | $11.2 0.72% 1M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: -0.25%
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: 1.0%
H: 10.4%
C: 10.4%
solution commercial ryzumvl apx3330
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
Published: 2024-03-08 (Crawled : 13:00) - globenewswire.com
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: -1.26%
H: 0.0%
C: -15.32%
pharma year update financial results
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Published: 2024-02-23 (Crawled : 13:00) - globenewswire.com
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: 0.8%
H: 0.34%
C: -0.79%
pharma ceo conference
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: -0.75%
H: 3.07%
C: 0.0%
pharma nasdaq grants
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
DERM | $3.58 13K
|
|
| O: 0.0%
H: 3.78%
C: -0.89%
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: 0.0%
H: 2.14%
C: 1.17%
pharma key
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: 0.75%
H: 0.37%
C: -5.62%
apx3330 pharma conference presentation
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-24 (Crawled : 21:00) - globenewswire.com
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: 0.0%
H: 0.74%
C: -0.37%
pharma nasdaq grants
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: 0.65%
H: 2.58%
C: 0.0%
fda pharma solution treatment trial agreement
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIIIInvestor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: 3.28%
H: 8.48%
C: 7.77%
pharma presentation innovation
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Last 48 Hours Insiders Buying
CLSD | $1.42 7.58% 100K
|
Health Technology
|
14:00
CDZI P 25000 | $2.275 1.11% 74K
|
Utilities
|
14:00
ETST P 39000 | $0.068 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.47 1.4% 6.6K
|
Finance
|
12:30
ADMQ | $0.0532 480K
|
|
10:30
AXR P 2400 | $22.26 0.41% 180
|
Finance
|
21:00
QCRH P 118 | $56.105 1.25% 11K
|
Finance
|
18:01
VUZI P 7500 | $1.245 -1.19% 140K
|
Electronic Technology
|
18:00
RMCF | $3.5501 390
|
Consumer Non-Durables
|
20:10